Skip to main content
. 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946

Table A1.

Microsatellite instability and tumor mutational burden testing in patients undergoing PCS.

Tumor Testing n (%)
MSI status (n = 110)
 MSS 106 (96.4%)
 MSI 1 (0.9%)
 Failed testing 3 (2.7%)
TMB (n = 94)
 Median (range) 1.82 (0–30.4)
 Low 93 (98.9%)
 High 1 (1.1%)

MSI = microsatellite instability. MSS = microsatellite stable. PCS = primary cytoreductive surgery. TMB = tumor mutational burden.